In this ancillary study, we assessed the prognostic value of previously-defined prognostic scores (such as the Royal Marsden Hospital (RMH) score) and of PD-L1, CD3, CD8 and FOXP3 expressions based on immunohistochemistry (IHC) and RNA sequencing (RNAseq) of tumor samples from patients included in the personalized-medicine MOSCATO-02 trial. PD-L1 and tumor-infiltrating lymphocytes play a key role in the immune escape of cancer, although their prognostic value remains unknown in patients with refractory solid cancer compared to other known prognostic estimation methods. No funding was received for conducting this study. Declaration of Competing InterestДЄuthors declare no conflict of interest. No ethical approval or informed consent was required for conducting the study. Data AvailabilityДata are available through the Surveillance, Epidemiology, and End Results (SEER) Program ( Ethical ApprovalДЄll data were obtained from the SEER database and no experiments with human were carried out.

All authors have approved the final version of the manuscript. All authors have contributed to article drafting and/or revision. MHO, HMB, HSG, SYF and MAR contributed to manuscript outline preparation. MHO, NAR, HSG and AOE contributed to statistical analysis and results generation. MHO, NAR, AOE, SYF, and HMB contributed to data acquisition and preprocessing. Old age, metastasis, large tumor size Author ContributionsДЄll authors contributed to the general project framework. Patients with SBS were older with smaller tumors and 60% of them received radiation for their primary tumors. The majority of patients had no nodal involvement or metastasis at diagnosis. We showed that PBS had better overall survival compared to SBS and hemangiosarcoma was the most common histologic subtype. Our study demonstrated the pathological characteristics, clinical features, and prognostic factors of PBS and SBS in a large population-based study. In this study, we provide a comprehensive analysis of clinical and pathological characteristics and prognostic factors of 1334 CONCLUSION While angiosarcoma is the most common type of breast sarcoma, there is a lack of information on the clinical and therapeutic aspects of other subtypes of breast sarcoma, with data mostly in the form of single institutional retrospective analyses. The is limited data regarding characteristics and optimal management of breast sarcoma due to the rarity of the disease. Patients with SBS had a significantly higher median age of 74.0 years, compared to the median age of patients with PBS (56.5 years). The clinical, pathological, and treatment characteristics of included patients are summarized in. Out of these patients, 816 had PBS and 518 had SBS. Tumor site was specified to include: C50.0-Nipple, C50.1-Central portion of breast, RESULTSДЄ total number of 1334 patients with breast sarcoma were diagnosed between 19 with a median survival of 69 months. Most cases of breast sarcoma are diagnosed at later stages with a worse prognosis than Data sourceДЇemale patients diagnosed with breast sarcoma between 19 were identified through the SEER database which collects data from 18 cancer registries, encompassing approximately 27.8% of the United States population 10. Although the clinical features of breast sarcomas can mimic those of breast carcinoma, no clear consensus 3. ДЇactors associated with worse survival of patients with primary breast sarcoma included being unmarried, age INTRODUCTIONД«reast sarcomas are an extremely rare and diverse group of malignancies comprising less than 1% of total breast malignancies and less than 5% of all soft tissue sarcomas with an annual incidence of 4.6 cases per million women 1, 2.Д«reast sarcomas can manifest either primary (de novo) or secondary.

Patients with primary sarcoma had better overall survival compared to patients with secondary sarcoma. On the other hand, radiation and chemotherapy did not show significant improvement in survival. Surgery was associated with better overall survival for primary and secondary sarcoma patients. Section snippets Clinical Practice PointsДЄbout 60% of patients with secondary breast sarcoma received radiation for their primary tumors.

Thomas panzarella